EMG
BLFS icon

Ellington Management Group’s BioLife Solutions BLFS Stock Holding History

Ellington Management Group’s Portfolio BLFS Stock Details BLFS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-10,700
Closed -$122K – 515
2018
Q2 		$122K Buy
+10,700
New +$97.4K 0.01% 451

Other funds holding BLFS

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
SCM
Sandler Capital Management New York $193M AUM 77.14% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Venator Capital Management Toronto, Ontario, Canada $48.7M AUM 87.97% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ellington Management Group's BLFS Position: Q3 2018 in Review

Ellington Management Group sold out of BioLife Solutions (BLFS) in Q3 2018, closing a stake of 10,700 shares — an estimated $122K sold.

Ellington Management Group first reported a position in BLFS in Q2 2018 and held it in 1 quarter. The position peaked at $122K in Q2 2018. 54 funds tracked by Wall St. Rank hold BLFS as of Q3 2018.

  • Ellington Management Group reported no remaining BioLife Solutions position as of Q3 2018 after selling out during the quarter.
  • Ellington Management Group sold 10,700 BioLife Solutions shares in Q3 2018, an estimated $122K.
  • Ellington Management Group first reported a position in BioLife Solutions in Q2 2018 and held it in 1 quarter.
  • Ellington Management Group's BioLife Solutions position peaked at $122K in Q2 2018.
  • 54 funds tracked by Wall St. Rank held BioLife Solutions as of Q3 2018.

Based on Ellington Management Group's 13F filing for Q3 2018, filed 14 Nov 2018.